Survival following disease recurrence of primary localized alveolar rhabdomyosarcoma
Pediatric Blood & Cancer2013Vol. 60(8), pp. 1267–1273
Citations Over Time
Tobias M. Dantonello, Christoph Int‐Veen, Andreas Schuck, Guido Seitz, Ivo Leuschner, Michaela Nathrath, Paul‐Gerhardt Schlegel, Udo Kontny, Wolfgang Behnisch, Iris Veit‐Friedrich, Stefanie Kube, Erika Hallmen, Bernarda Kazanowska, Ruth Ladenstein, Michael Paulussen, Gustaf Ljungman, Stefan Bielack, T. Klingebiel, Ewa Kościelniak, on behalf of the Cooperative Weichteilsarkom Studiengruppe (CWS)
Abstract
Post-relapse survival for primary localized RMA is generally poor. However, certain patient groups differed significantly in their likelihood of survival and 50% of patients with circumscribed relapses treated with ALRT survived. These findings may form the basis for an evidence-based risk-stratification for recurrent disease including relapse treatment.
Related Papers
- → Protein kinase C iota as a therapeutic target in alveolar rhabdomyosarcoma(2012)31 cited
- → Preclinical Testing of Erlotinib in a Transgenic Alveolar Rhabdomyosarcoma Mouse Model(2011)13 cited
- → Clinical Relevance of Molecular Diagnosis in Childhood Rhabdomyosarcoma(2000)37 cited
- → Refractory alveolar rhabdomyosarcoma in an 11-year-old male(2021)3 cited
- → Alveolar Sinonasal Rhabdomyosarcoma in Adults: A Case Report(2013)